Last: | $10.69 |
---|---|
Change Percent: | -0.47% |
Open: | $10.63 |
Close: | $10.69 |
High: | $10.7 |
Low: | $10.63 |
Volume: | 145,981 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$10.69 | $10.63 | $10.69 | $10.7 | $10.63 | 145,981 | 05-03-2024 |
$10.58 | $10.53 | $10.58 | $10.59 | $10.51 | 100,544 | 05-02-2024 |
$10.54 | $10.5 | $10.54 | $10.58 | $10.5 | 132,029 | 05-01-2024 |
$10.5 | $10.5 | $10.5 | $10.53 | $10.495 | 120,828 | 04-30-2024 |
$10.56 | $10.55 | $10.56 | $10.57 | $10.54 | 77,138 | 04-29-2024 |
$10.55 | $10.51 | $10.55 | $10.58 | $10.51 | 86,460 | 04-26-2024 |
$10.52 | $10.55 | $10.52 | $10.55 | $10.505 | 158,624 | 04-25-2024 |
$10.6 | $10.62 | $10.6 | $10.66 | $10.6 | 100,481 | 04-24-2024 |
$10.64 | $10.6 | $10.64 | $10.67 | $10.6 | 60,646 | 04-23-2024 |
$10.61 | $10.64 | $10.61 | $10.66 | $10.6 | 122,449 | 04-22-2024 |
$10.65 | $10.66 | $10.65 | $10.71 | $10.63 | 134,290 | 04-19-2024 |
$10.64 | $10.77 | $10.64 | $10.77 | $10.64 | 110,954 | 04-18-2024 |
$10.73 | $10.71 | $10.73 | $10.76 | $10.69 | 120,786 | 04-17-2024 |
$10.7 | $10.64 | $10.7 | $10.745 | $10.64 | 98,367 | 04-16-2024 |
$10.71 | $10.76 | $10.71 | $10.79 | $10.7 | 146,239 | 04-15-2024 |
$10.82 | $10.85 | $10.82 | $10.87 | $10.81 | 80,355 | 04-12-2024 |
$10.7975 | $10.7676 | $10.7975 | $10.8274 | $10.7378 | 119,124 | 04-11-2024 |
$10.84 | $10.88 | $10.84 | $10.88 | $10.82 | 163,797 | 04-10-2024 |
$10.96 | $10.95 | $10.96 | $10.96 | $10.88 | 127,393 | 04-09-2024 |
$10.88 | $10.85 | $10.88 | $10.92 | $10.85 | 47,022 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Blackrock MuniYield Fund Inc. Company Name:
MYD Stock Symbol:
NYSE Market:
SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the...
SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest GeneSight Mental Health Monitor, a ...
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study 1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 micr...